Golden State Equity Partners’s Beam Therapeutics BEAM Stock Holding History

Golden State Equity Partners’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25	Closed	-$595	–	472
2026 Q1	$595	Buy	+25	New	+$694	﹤0.01%	1859
2024 Q4	–	Sell	-260	Closed	-$6.37K	–	488
2024 Q3	$6.37K	Buy	+260	New	+$6.72K	﹤0.01%	739
2022 Q1	$555K	Buy	9,690 +3,090	+47%	+$203K	0.28%	101
2021 Q4	$526K	Buy	+6,600	New	+$565K	0.27%	88

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Golden State Equity Partners's BEAM Position: Q2 2026 in Review

Golden State Equity Partners sold out of Beam Therapeutics (BEAM) in Q2 2026, closing a stake of 25 shares — an estimated $595 sold.

Golden State Equity Partners first reported a position in BEAM in Q4 2021 and held it in 4 quarters. The position peaked at $555K in Q1 2022. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Golden State Equity Partners reported no remaining Beam Therapeutics position as of Q2 2026 after selling out during the quarter.
Golden State Equity Partners sold 25 Beam Therapeutics shares in Q2 2026, an estimated $595.
Golden State Equity Partners first reported a position in Beam Therapeutics in Q4 2021 and held it in 4 quarters.
Golden State Equity Partners's Beam Therapeutics position peaked at $555K in Q1 2022.
278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.